Oruka Therapeutics’ (ORKA) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $151.00 price objective on the stock.

ORKA has been the topic of several other reports. Mizuho set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, September 3rd. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Wedbush reaffirmed an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.80.

Oruka Therapeutics Trading Down 2.0%

Shares of ORKA opened at $104.99 on Tuesday. Oruka Therapeutics has a fifty-two week low of $25.23 and a fifty-two week high of $115.51. The firm has a 50-day simple moving average of $89.39 and a 200-day simple moving average of $72.01.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). Equities research analysts predict that Oruka Therapeutics will post -2.50 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In related news, CEO Lawrence Klein sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares in the company, valued at $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the business’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the sale, the senior vice president directly owned 14,219 shares in the company, valued at approximately $1,146,051.40. This represents a 41.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 169,950 shares of company stock valued at $15,426,080 in the last ninety days. 23.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ORKA. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $474,916,000. Jupiter Topco LLC purchased a new position in Oruka Therapeutics in the 2nd quarter valued at approximately $130,968,000. Remedium Capital Partners LLC increased its stake in Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after purchasing an additional 13,247 shares in the last quarter. Avidity Partners Management LP increased its stake in Oruka Therapeutics by 15.1% in the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Voya Investment Management LLC raised its holdings in Oruka Therapeutics by 2.9% during the third quarter. Voya Investment Management LLC now owns 412,814 shares of the company’s stock worth $34,383,000 after purchasing an additional 11,665 shares during the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Oruka Therapeutics

These are some of the ORKA headlines that stood out recently:

• Positive Sentiment: BTIG Research and UBS each initiated or reiterated a “Buy” view on Oruka Therapeutics, signaling analyst confidence. BTIG Research Buy-rating article UBS Buy-rating article
• Neutral Sentiment: Phase 2 psoriasis results could be a significant upcoming catalyst for the stock, but the article does not report new trial results. Phase 2 psoriasis results article
• Negative Sentiment: HC Wainwright lowered its quarterly and full-year EPS estimates through 2027, including its FY2027 forecast from a loss of $2.82 to a loss of $3.22 per share. The analyst maintained a Buy rating, but the deeper projected losses may weigh on sentiment.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.